Merck Serono to Introduce RebiSlide(TM), the Rebif(R) Multidose Manual Pen-injector for Multiple Sclerosis Treatment

GENEVA, Switzerland, June 8, 2012 /PRNewswire/ —

Merck Serono, a division of Merck, Darmstadt, Germany, announced today the forthcoming introduction of the new injection device RebiSlide(TM) in Europe and Canada, followed by other countries. RebiSlide(TM) is a multidose manual injection pen for the self-administration of Rebif(R) (interferon beta-1a), a disease-modifying drug used to treat relapsing forms of multiple sclerosis (MS).

“RebiSlide(TM) is the latest addition to Merck Serono´s range of injection devices for the self-administration of Rebif(R) to meet the needs of patients looking for a compact and multidose device, ” said Belen Garijo, Head of Global Operations at Merck Serono. “The introduction of RebiSlide(TM), alongside other innovative devices such as the electronic multidose device RebiSmart(TM) and the single-use pre-filled pen RebiDose(TM), underscores our commitment to continuous advancement in multiple sclerosis treatments, by offering patients different administration options to suit their individual needs.”

RebiSlide(TM) is a manual multidose injection device for MS therapy and was designed to offer an alternative way of injection for patients with relapsing multiple sclerosis looking for a portable and multidose device. RebiSlide(TM) uses the multidose cartridges of Rebif(R) containing a week´s supply of Rebif(R) therapy (three doses of 44 micrograms or three doses of 22 micrograms). The device contains a dose window, which allows users to select the dose of injection prescribed, including dose titration (8.8 micrograms or 22 micrograms).

..

 Please note that all comments are moderated.